<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897257</url>
  </required_header>
  <id_info>
    <org_study_id>146-9252-201</org_study_id>
    <nct_id>NCT03897257</nct_id>
  </id_info>
  <brief_title>A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blinded, Parallel Group Comparison Study of the Safety and Efficacy of UHE-103 in Subjects With Moccasin-Type Tinea Pedis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being done to determine and compare the safety and effectiveness of an
      investigational combination therapy (low and high concentrations) versus mono-therapy (low
      and high concentrations) or mono-therapy (fixed concentration) in subjects with moccasin type
      tinea pedis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      UHE-103 cream is an investigational combination drug to treat moccasin type tinea pedis, a
      fungal infection that affects the feet and toes. Eligible subjects will be assigned to one of
      the 5 possible treatment groups and participate for a total of 6 weeks. Subjects will apply
      their assigned test drug twice daily for 2 weeks. Each subject will then be assessed for
      safety and efficacy at week 4 and week 6. There will be a total of 5 clinic visits: 1
      screening/baseline visit (Day 1), 2 treatment visits (Days 8 and 15), and 2 follow-up visits
      (Days 29 and 43).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Anticipated">December 27, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Five Arms:
3 Arms of Monotherapy : UHE-103A1 cream (Drug A low dose concentration) or UHE-103A2 cream (Drug A high concentration) or UHE-103B cream (Drug B comparator)
2 Arms of combination therapy: UHE-103A1B cream (Drug A low dose + Drug B), or UHE-103A2B cream (Drug A high dose + Drug B)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Cure at End of Study</measure>
    <time_frame>Day 43</time_frame>
    <description>Proportion of subjects with Complete Cure (negative fungal test &amp; no clinical disease-induced signs and symptoms) at end of study (EOS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effective treatment</measure>
    <time_frame>Day 43</time_frame>
    <description>Proportion of subjects with Effective Treatment (negative fungal test &amp; no to mild clinical disease-induced signs and symptoms) at EOS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological Cure</measure>
    <time_frame>Day 43</time_frame>
    <description>Proportion of subjects with Mycological Cure (negative fungal test) at EOS.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>UHE-103A1 cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical cream applied twice daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UHE-103A2 cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical cream applied twice daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UHE-103B cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical cream applied twice daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UHE-103A1B cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical cream applied twice daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UHE-103A2B cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical cream applied twice daily for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UHE-103A1 cream</intervention_name>
    <description>Investigational mono-therapy cream (containing drug A [low dose])</description>
    <arm_group_label>UHE-103A1 cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UHE-103A2 cream</intervention_name>
    <description>Investigational mono-therapy cream (containing drug A [low dose])</description>
    <arm_group_label>UHE-103A2 cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UHE-103B cream</intervention_name>
    <description>Comparator mono-therapy cream (containing drug B)</description>
    <arm_group_label>UHE-103B cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UHE-103A1B cream</intervention_name>
    <description>Investigational combination-therapy cream (containing drug A [low dose] + drug B)</description>
    <arm_group_label>UHE-103A1B cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UHE-103A2B cream</intervention_name>
    <description>Investigational combination-therapy cream (containing drug A [high dose] + drug B)</description>
    <arm_group_label>UHE-103A2B cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant female, 16 years of age or older.

          -  Clinical diagnosis of moccasin type tinea pedis

          -  Microscopic evidence (positive KOH) of the presence of fungi

          -  Provided written informed consent/assent

          -  In general good health

        Exclusion Criteria:

          -  Pregnant or lactating or planning to get pregnant while on the study

          -  Has concurrent tinea infection (e.g., tinea versicolor, tinea cruris)

          -  Other skin disease which might interfere with the evaluation of tinea pedis

          -  History of diabetes mellitus or is immunocompromised

          -  Currently enrolled in an investigational drug or device study

          -  Used an investigational drug or investigational device treatment within 30 days prior
             to Visit 1 (Study Day 1)/Baseline

        Other protocol defined inclusion or exclusion criteria assessed by the study staff may
        apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marietta Radona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 06</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 09</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 07</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 04</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 05</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 08</name>
      <address>
        <city>Cidra</city>
        <zip>00739</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

